These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 22128076

  • 1. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
    Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores-Suarez LF, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage CO, Jayne D, EUVAS investigators.
    Ann Rheum Dis; 2012 Jun; 71(6):955-60. PubMed ID: 22128076
    [Abstract] [Full Text] [Related]

  • 2. [Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis (CYCLOPS study)].
    Kötter I.
    Z Rheumatol; 2009 Sep; 68(7):575-7. PubMed ID: 19652987
    [No Abstract] [Full Text] [Related]

  • 3. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
    de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, EUVAS (European Vasculitis Study Group).
    Ann Intern Med; 2009 May 19; 150(10):670-80. PubMed ID: 19451574
    [Abstract] [Full Text] [Related]

  • 4. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis--preliminary single center experience.
    Rihová Z, Jancová E, Merta M, Zabka J, Rysavá R, Bartůnková J, Kolárova I, Tesar V.
    Prague Med Rep; 2004 May 19; 105(1):64-8. PubMed ID: 15354947
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR.
    Arthritis Rheum; 2005 Aug 19; 52(8):2461-9. PubMed ID: 16052573
    [Abstract] [Full Text] [Related]

  • 6. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
    Slot MC, Tervaert JW, Boomsma MM, Stegeman CA.
    Arthritis Rheum; 2004 Apr 15; 51(2):269-73. PubMed ID: 15077271
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement.
    Rihova Z, Jancova E, Merta M, Rysava R, Reiterova J, Zabka J, Tesar V.
    Kidney Blood Press Res; 2005 Apr 15; 28(3):144-52. PubMed ID: 15908752
    [Abstract] [Full Text] [Related]

  • 8. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.
    Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, Brunkhorst R.
    Arthritis Rheum; 1998 Oct 15; 41(10):1835-44. PubMed ID: 9778225
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
    Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C, European Vasculitis Study Group.
    N Engl J Med; 2003 Jul 03; 349(1):36-44. PubMed ID: 12840090
    [Abstract] [Full Text] [Related]

  • 10. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
    Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA.
    Rheumatology (Oxford); 2006 Jun 03; 45(6):724-9. PubMed ID: 16399845
    [Abstract] [Full Text] [Related]

  • 11. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R, Stojanović R, Novicić-Sasić D, Dimitrijević J, Pavlović S, Stojković D, Palić-Obradović D, Stevanović G, Prodanović S.
    Srp Arh Celok Lek; 2002 Aug 03; 130 Suppl 3():19-25. PubMed ID: 12583309
    [Abstract] [Full Text] [Related]

  • 12. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
    Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, Kyndt X, Lifermann F, Papo T, Lambert M, Le Noach J, Khellaf M, Merrien D, Puéchal X, Vinzio S, Cohen P, Mouthon L, Cordier JF, Guillevin L, French Vasculitis Study Group.
    N Engl J Med; 2008 Dec 25; 359(26):2790-803. PubMed ID: 19109574
    [Abstract] [Full Text] [Related]

  • 13. Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    Faurschou M, Westman K, Rasmussen N, de Groot K, Flossmann O, Höglund P, Jayne DR, European Vasculitis Study Group.
    Arthritis Rheum; 2012 Oct 25; 64(10):3472-7. PubMed ID: 22614882
    [Abstract] [Full Text] [Related]

  • 14. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
    Hebert LA, Rovin BH.
    Ann Intern Med; 2010 Jan 05; 152(1):64; author reply 65. PubMed ID: 20048278
    [No Abstract] [Full Text] [Related]

  • 15. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
    Levine SM.
    Ann Intern Med; 2010 Jan 05; 152(1):65; author reply 65. PubMed ID: 20048281
    [No Abstract] [Full Text] [Related]

  • 16. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
    Padhan P.
    Ann Intern Med; 2010 Jan 05; 152(1):64; author reply 65. PubMed ID: 20048279
    [No Abstract] [Full Text] [Related]

  • 17. Optimizing the therapeutic strategies in ANCA-associated vasculitis--single centre experience with international randomized trials.
    Vanková Z, Ríhová Z, Jancová E, Rysavá R, Merta M, Tesar V.
    Prague Med Rep; 2006 Jan 05; 107(2):199-212. PubMed ID: 17066740
    [Abstract] [Full Text] [Related]

  • 18. Prolonged treatment with low-dose intravenous pulse cyclophosphamide may reduce rate of relapse in ANCA-associated vasculitis.
    Dhaygude A, Griffith M, Cairns T, McLean A, Palmer A, Taube D.
    Nephron Clin Pract; 2004 Jan 05; 97(4):c154-9. PubMed ID: 15331939
    [Abstract] [Full Text] [Related]

  • 19. Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis.
    Almroth G, Berlin G, Andersson B, Hahn-Zoric M.
    Scand J Urol Nephrol; 2009 Jan 05; 43(2):160-70. PubMed ID: 18979374
    [Abstract] [Full Text] [Related]

  • 20. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies.
    Brijker F, Magee CC, Tervaert JW, O'Neill S, Walshe JJ.
    Clin Nephrol; 1999 Dec 05; 52(6):344-51. PubMed ID: 10604641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.